Armata appoints Dr. Daniel Gilmer to Board; option award for 51,280 shares

Armata Pharmaceuticals, Inc.

Dr. Daniel Gilmer (39) appointed to Board effective April 24, 2026.
He will receive an option award to purchase 51,280 shares vesting over three years.
Non-management directors receive a cash retainer of $40,000 per year.
Gilmer is Senior Director at Pfizer and led the U.S. launch of PAXLOVID.
He is co-inventor of Streptococcus phage lysin exebacase (CF-301).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.